Condition: Advanced Solid Tumors · Sponsor: Amgen
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists - Fort Myers | Fort Myers, Florida, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Terminated |
| Centre Leon Berard | Lyon, France | Recruiting |
| Evangelische Lungenklinik | Berlin, Germany | Recruiting |
| Henry Dunant Hospital Center | Athens, Greece | Recruiting |
| Theagenion Cancer Hospital | Thessaloniki, Greece | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma, Italy | Recruiting |
| National Hospital Organization Hokkaido Cancer Center | Sapporo, Hokkaido, Japan | Terminated |
| Universitaetsspital Basel | Basel, Switzerland | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07172919